Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Want to cut your energy bills? Here’s how five experts are doing it 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
CAMBRIDGE, Mass., Feb. 27, 2017 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the following investor conferences:
- Cowen and Company 37th Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2017 at 10:40am ET with a live webcast at www.vcel.com/events.
- 29th Annual ROTH Conference in Dana Point, CA on Monday, March 13, 2017 at 8:00am PT with a live webcast at www.vcel.com/events.
- 2017 Canaccord Genuity Musculoskeletal Conference in San Diego, CA on Tuesday, March 14, 2017 at 11:00am PT with a live webcast at www.vcel.com/events.
About Vericel Corporation
Vericel develops, manufactures, and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions. The company markets three cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults, which has recently been approved by the FDA. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing ixmyelocel-T, an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
